AI Article Synopsis
- Bispecific antibodies (BsAb) can target both tumor cells and the CD3 molecule to activate T cells for fighting minimal residual disease in cancer therapy.
- A new trispecific antibody (scTsAb) was developed to enhance T cell activity by combining anti-ovarian carcinoma specificity with CD3 and CD28 components, improving T cell survival and effectiveness.
- The scTsAb demonstrated strong binding and activation of T cells, leading to significant cytotoxic effects on ovarian cancer cells, representing a promising advancement in cancer immunotherapy.
Article Abstract
Bispecific antibodies (BsAb) with specificity to both tumor cells and CD3 molecule were believed to be promising immunological tools for the therapy with minimal residual diseases by activating cytotoxic T cells. However, without costimulatory molecule CD28, the activated T cells tended to apoptosis. In order to kill tumor cells more efficiently, a recombinant multifunctional single-chain trispecific antibody (scTsAb), which contains anti-ovarian carcinoma (OC) scFv, anti-CD3 scFv and VH domain of anti-CD28 antibody, was constructed and expressed in E. coli BL21 Star strain. The scTsAb showed strong binding avidities to membrane antigen of SK-OV-3 cell, CD3 molecule on Jurkat cell, and recombinant CD28 antigen. It was further demonstrated that this scTsAb could activate peripheral blood T cells to elicit strong cytotoxicity against SK-OV-3 cells. This new type of recombinant scFv antibody set up a new technological platform for T cells based immunotherapy against cancer, especially with the failure on MHC antigen presentation or absence of costimulating signal.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Boosting Natural Killer Cells' Immunotherapy with Amoxicillin-Loaded Liposomes.
Mol Pharm
January 2025
State Key Laboratory for Organic Electronics and Information Displays & Jiangsu Key Laboratory for Biosensors, Institute of Advanced Materials (IAM), Nanjing University of Posts & Telecommunications, Nanjing 210023, China.
Natural killer (NK) cell immunotherapy is a significant category in tumor therapy due to its potent tumor-killing and immunomodulatory effects. This research delves into exploring the mechanisms underlying the ability of amoxicillin to boost NK cell cytotoxicity in NK cell immunotherapy. Amoxicillin significantly enhances the cytotoxic activity of NK-92MI cells against MCF-7 cells by triggering the initiation of a cytolytic program in target cell-deficient NK-92MI cells and augmenting the degranulation level of NK-92MI cells in the presence of target cells.
View Article and Find Full Text PDFMacrophage activity modulation via synergistic effect of a porous substrate and low-field laser therapy.
Acta Bioeng Biomech
June 2024
1Institute of Applied Sciences, Academy of Physical Education, Kraków, Poland.
: The aim of this study was to investigate the effect of substrate - polycaprolactone (PCL)-based porous membrane modified with rosmarinic acid (RA), (PCL-RA) and to determine the optimal values of low field laser irradiation (LLLT) as stimulators of biological response of RAW 264.7 macrophages. : The porous polymer membrane was obtained by the phase inversion method, the addition of rosmarinic acid was 1%wt.
View Article and Find Full Text PDFDeciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alpha.
Blood Adv
January 2025
Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.
Interferon alpha (IFNa) is approved for the therapy of patients (pts) with polycythemia vera (PV), a subtype of myeloproliferative neoplasms (MPN). Some pts achieve molecular responses (MR), but clonal factors sensitizing for MR remain elusive. We integrated colony formation and differentiation assays with single-cell RNA seq and genotyping in PV-derived cells vs.
View Article and Find Full Text PDFToll-like receptor 1/2 activation reduces immunoglobulin free light chain production by multiple myeloma cells in the context of bone marrow stromal cells and fibronectin.
PLoS One
January 2025
Division of Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
Toll-like receptor (TLRs) activation in multiple myeloma (MM) cells induces heterogeneous functional responses including cell growth and proliferation, survival or apoptosis. These effects have been suggested to be partly due to increase in secretion of cytokines such as IL-6 or IFNα among others from MM cells following TLR activation. However, whether triggering of these receptors also modulates production of immunoglobulin free light chains (FLCs), which largely contribute to MM pathology, has not been investigated in MM cells before.
View Article and Find Full Text PDFEven though Leydig cell tumor (LCT) represents the most common neoplasia among testicular sex cord-stromal tumors (SCSTs), it is a rare condition, comprising 1-2% of all testicular tumors, with a 10% risk of malignancy most commonly located in retroperitoneal lymph nodes. LCTs may demonstrate various clinical manifestations - from asymptomatic intratesticular swelling through nonspecific symptoms such as loss of libido, impotence or infertility, up to feminizing or virilizing syndromes due to hormonal activity of the tumor. This article presents a case of Leydig cell tumor that was associated with azoospermia what have rarely been reported worldwide.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!